Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Small Cap

Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August

By Ragothaman Srinivasan
July 29, 4:36 PM
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ: ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older.

ARQT

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Price Target
  • Trading Ideas

Duchenne Gene Therapy Firm Sarepta Therapeutics’ Earns 8% Price Target Hike From This Analyst

By Vandana Singh
July 29, 1:53 PM
Earlier today, Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that it would submit the marketing application and seek accelerated FDA approval for SRP-9001 in…

SRPT

Read More
1 minute read
  • General
  • Health Care
  • Legal
  • News

CVS Health Sued For Taking Money From Hospitals Serving Low-Income Patients: Report

By Vandana Singh
July 29, 1:49 PM
Attorney General Letitia James filed a lawsuit in New York, claiming that CVS Health Corp (NYSE:CVS) violated state antitrust law…

CVS

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

AstraZeneca Drops Moderna-Partnered, Phase 2 Heart Disease Drug Candidate

By Vandana Singh
July 29, 1:46 PM
AstraZeneca Plc (NASDAQ: AZN) has removed a Moderna Inc (NASDAQ: MRNA)-partnered cardiovascular disease candidate from its phase 2 pipeline. 

AZN

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Novo Nordisk Once-Weekly Insulin Hits Primary Goals In In Two Phase 3 Trials

By Vandana Singh
July 29, 1:42 PM
Novo Nordisk A/S (NYSE:NVO) announced headline results from the ONWARDS 3 and ONWARDS 4 Phase 3a trials with once-weekly insulin icodec…

NVO

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Small Cap

Enanta Shares Rise On Positive Data From Initial-Stage Covid Study

By Ragothaman Srinivasan
July 29, 11:32 AM
Enanta Pharmaceuticals (NASDAQ: ENTA) reported positive topline data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of orally administered single and multiple ascending doses of EDP-235 in healthy adult subjects.

ENTA

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers & Shakers
  • News
  • Penny Stocks
  • Small Cap

Omeros Shares Climb As FDA Grants Orphan Drug Status To Blood Disorder Candidate

By Ragothaman Srinivasan
July 29, 10:06 AM
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Omeros Corporation’s (NASDAQ: OMER) lead asset OMS906 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

OMER

Read More
1 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • News

AbbVie’s Q2 Sales Marginally Shy Of Wall Street Estimates, Confirms Annual Profit Outlook

By Vandana Singh
July 29, 8:35 AM
AbbVie Inc (NYSE:ABBV) reports Q2 adjusted EPS of $3.37, up 11.2% Y/Y and beating the consensus of $3.33. Overall sales…

ABBV

Read More
1 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

AstraZeneca Q2 Highlights: Profits Fall, COVID-19 Vaccine Sales Dip, Lifts Annual Sales Guidance

By Vandana Singh
July 29, 6:04 AM
AstraZeneca Plc (NASDAQ:AZN) Q2 profits fell sharply on ballooning costs linked to its Alexion takeover. The net profit was down…

AZN

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Legal
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Bausch Health To Appeal Expected Court Decision On Xifaxan Patents

By Vandana Singh
July 29, 5:01 AM
Yesterday, Bausch Health Companies Inc (NYSE: BHC) stock closed 50% lower after the reports on the order on patent litigation over Xifaxan (rifaximin).

BHC

Posts pagination

Previous 1 … 456 457 458 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service